Alogabat

Alogabat
Clinical data
Other names	GABA-Aa5 PAM; GABA-Aα5 PAM; RG-7816; RG7816; RO-7017773; RO7017773
Routes of; administration	Oral
Drug class	α5 subunit-containing GABAA receptor positive allosteric modulator
Identifiers
	IUPAC name 6-[[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy]-N-(oxan-4-yl)pyridazine-3-carboxamide;
CAS Number	2230009-48-8;
PubChem CID	134588268;
DrugBank	DB18708;
ChemSpider	115006746;
UNII	0HPA4GK3UH;
KEGG	D12382;
ChEMBL	ChEMBL5095259;
Chemical and physical data
Formula	C21H23N5O4
Molar mass	409.446 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NC=C(C=C1)C2=NOC(=C2COC3=NN=C(C=C3)C(=O)NC4CCOCC4)C;
	InChI InChI=1S/C21H23N5O4/c1-13-3-4-15(11-22-13)20-17(14(2)30-26-20)12-29-19-6-5-18(24-25-19)21(27)23-16-7-9-28-10-8-16/h3-6,11,16H,7-10,12H2,1-2H3,(H,23,27); Key:ACZCJTHHWMBFKC-UHFFFAOYSA-N;

Alogabat (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names RG-7816 and RO7017773) is an α₅ subunit-containing GABA_A receptor positive allosteric modulator which is under development for the treatment of pervasive developmental disorders (e.g., autism) and Angelman syndrome.^[1]^[2]^[3]^[4] It is taken by mouth.^[1]

As of June 2024, alogabat is in phase 2 clinical trials for pervasive developmental disorders and Angelman syndrome.^[1]^[2] It is under development by Roche.^[1]^[2]

References

^ ^a ^b ^c ^d ^e "Alogabat - Genentech". AdisInsight. 28 June 2024. Retrieved 29 October 2024.
^ ^a ^b ^c "Delving into the Latest Updates on RG-7816 with Synapse". Synapse. 19 September 2024. Retrieved 29 October 2024.
^ Maramai S, Benchekroun M, Ward SE, Atack JR (April 2020). "Subtype Selective γ-Aminobutyric Acid Type A Receptor (GABA_AR) Modulators Acting at the Benzodiazepine Binding Site: An Update". Journal of Medicinal Chemistry. 63 (7): 3425–3446. doi:10.1021/acs.jmedchem.9b01312. PMID 31738537.
^ Stevens EB, Stephens GJ (2024). "Ion Channels as Targets in Drug Discovery: Outlook and Perspectives". Ion Channels as Targets in Drug Discovery. Cham: Springer International Publishing. p. 1–34. doi:10.1007/978-3-031-52197-3_1. ISBN 978-3-031-52196-6.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[AdisInsight-1] "Alogabat - Genentech". AdisInsight. 28 June 2024. Retrieved 29 October 2024.

[Synapse-2] "Delving into the Latest Updates on RG-7816 with Synapse". Synapse. 19 September 2024. Retrieved 29 October 2024.

[MaramaiBenchekrounWard2020-3] Maramai S, Benchekroun M, Ward SE, Atack JR (April 2020). "Subtype Selective γ-Aminobutyric Acid Type A Receptor (GABA_AR) Modulators Acting at the Benzodiazepine Binding Site: An Update". Journal of Medicinal Chemistry. 63 (7): 3425–3446. doi:10.1021/acs.jmedchem.9b01312. PMID 31738537.

[StevensStephens2024-4] Stevens EB, Stephens GJ (2024). "Ion Channels as Targets in Drug Discovery: Outlook and Perspectives". Ion Channels as Targets in Drug Discovery. Cham: Springer International Publishing. p. 1–34. doi:10.1007/978-3-031-52197-3_1. ISBN 978-3-031-52196-6.

[1]

[2]

[3]

[4]

Clinical data

Other names	GABA-Aa5 PAM; GABA-Aα5 PAM; RG-7816; RG7816; RO-7017773; RO7017773
Routes of administration	Oral^[1]
Drug class	α₅ subunit-containing GABA_A receptor positive allosteric modulator
Identifiers
IUPAC name 6-[[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy]-N-(oxan-4-yl)pyridazine-3-carboxamide
CAS Number	2230009-48-8
PubChem CID	134588268
DrugBank	DB18708
ChemSpider	115006746
UNII	0HPA4GK3UH
KEGG	D12382
ChEMBL	ChEMBL5095259
Chemical and physical data
Formula	C₂₁H₂₃N₅O₄
Molar mass	409.446 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=NC=C(C=C1)C2=NOC(=C2COC3=NN=C(C=C3)C(=O)NC4CCOCC4)C
InChI InChI=1S/C21H23N5O4/c1-13-3-4-15(11-22-13)20-17(14(2)30-26-20)12-29-19-6-5-18(24-25-19)21(27)23-16-7-9-28-10-8-16/h3-6,11,16H,7-10,12H2,1-2H3,(H,23,27) Key:ACZCJTHHWMBFKC-UHFFFAOYSA-N

Alogabat

See also

References